Ignite Creation Date:
2024-05-06 @ 7:12 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05927857
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-07-03
First Post:
2023-06-14
Brief Title:
Ramucirumab Cyramza Nal-IRI ONIVYDE and TrifluridineTipiracil Lonsurf in Second Line Metastatic Gastric Cancer
Sponsor:
Organization:
National Health Research Institutes Taiwan
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
45
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: